Can AAV Antibodies Affect DMD Gene Therapy Eligibility?

If your child tests positive for AAV (adeno-associated virus) antibodies before receiving a Duchenne muscular dystrophy (DMD) gene therapy like Elevidys, it means their immune system has previously been exposed to a naturally occurring virus that is similar to the therapy, and has built a defense against it ^[1]. This test does not mean your child has an active infection, nor does it mean they are contagious. A detectable or low-level antibody result is not necessarily the same as being permanently ineligible. However, if their antibody levels are at or above a specific threshold set by the therapy’s current prescribing guidelines, they typically do not meet the screening criteria for the treatment ^[2][3].

The Role of the AAV Vector

Gene therapies need a delivery vehicle, called a vector, to transport new genetic material into the body’s cells. Elevidys uses a specific viral vector known as AAVrh74 ^[4]. Scientists use adeno-associated viruses (AAVs) because naturally occurring AAVs are not known to cause disease in humans, making them useful for carrying therapies ^[5].

For Elevidys, the original viral DNA has been removed and replaced with a shortened, engineered version of the dystrophin gene, called micro-dystrophin ^[6]. The therapy is administered through an intravenous (IV) infusion, allowing the vector to travel through the bloodstream and enter muscle and heart cells ^[4]. The AAVrh74 vector is not just a simple envelope; its outer shell (capsid) helps determine which tissues it targets, but it can also be recognized by the immune system ^[1]. While the vector cannot copy itself like a normal virus, it can still trigger serious immune and liver complications when given at therapeutic doses ^[7][8].

Why Pre-Existing Immunity Matters

Because naturally occurring AAVs are common in the environment, many children are exposed to them during daily life without ever showing symptoms. Their immune system then creates antibodies—proteins designed to recognize and bind to the virus if it returns ^[1]. The screening test for Elevidys looks for total-binding antibodies, which are antibodies that attach to any part of the AAVrh74 vector ^[3].

If a child has high levels of these antibodies, the immune system may recognize the gene therapy and bind to the vector ^[1]. This binding can promote the clearance of the therapy from the body or prevent it from efficiently entering the muscle cells, potentially reducing how well the treatment works ^[9][1]. Additionally, giving the therapy to a child with high pre-existing antibody levels could increase the risk of severe immune or hypersensitivity reactions ^[10][11]. Because of these delivery challenges and safety risks, children with antibody levels above a certain cutoff were generally excluded from the early clinical trials supporting the authorization of Elevidys, meaning its safety and effectiveness are not established for that group ^[4].

It is also important to note that Elevidys carries serious safety warnings for all patients, including the risk of acute liver injury, myositis (muscle inflammation), and myocarditis (heart inflammation) ^[7][8]. The medical team must carefully weigh these risks, along with antibody status, when considering treatment.

Screening and Antibody Thresholds

Before receiving Elevidys, children must undergo a specific blood test to check their anti-AAVrh74 antibody levels ^[3]. The result is reported as a titer, which is a laboratory measurement of how much the blood sample can be diluted while still detecting the antibodies. A larger number indicates more antibodies are present.

According to current prescribing information and treatment guidelines, treatment with Elevidys is not recommended if a child’s total-binding anti-AAVrh74 antibody titer is at or above 1:400 (meaning ≥ 1:400) ^[2][3].

• Below 1:400: The child meets the current antibody screening criteria for Elevidys ^[2].
• At or Above 1:400: The child is considered seropositive above the threshold and typically does not meet the eligibility criteria for the therapy ^[2][3].

Antibody status is not the only factor in determining if a child can receive Elevidys. Eligibility also depends on the child’s age, functional status, their specific DMD genetic mutation, and a careful review of their overall health by a neuromuscular specialist.

Research on Overcoming Antibodies

Testing above the antibody threshold is a major hurdle in current DMD treatment, but it is one of the most active areas of medical research. Scientists are testing experimental strategies to clear antibodies or hide the vector from the immune system. It is crucial to understand that these approaches are highly investigational, carry their own medical risks, and should only be considered as part of a formal clinical trial. They are not standard treatments families can pursue independently:

• Plasmapheresis and Immunoadsorption: These blood-filtering techniques attempt to temporarily remove antibodies from the child’s bloodstream ^[12][13].
• IgG-Degrading Enzymes: Researchers are testing specialized enzymes designed to temporarily break down a specific class of antibodies (IgG), creating a brief window for the gene therapy to safely enter the cells ^[14][15].
• Vector Switching and Engineered Capsids: Scientists are trying to develop different AAV types (serotypes) or disguised vectors that the child’s immune system will not immediately recognize ^[16][17].

If your child is currently ineligible for gene therapy, this does not mean they are without options. Other disease-modifying treatments, such as mutation-specific exon-skipping therapies, corticosteroids, physical therapy, and proactive cardiac and respiratory care, remain essential components of managing DMD.